Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical outcomes prior to anti-PD(L)-1 inhibition monotherapy (IO) has been demonstrated in multiple studies, but the impact of antibiotic exposure prior to initiation of Chemo-IO is controversial. We assessed antibiotic exposures at two time windows: within 60 days prior to therapy (-60 d window) and within 60 days prior to therapy and 42 days after therapy (-60 + 42d window) in 2028 patients with advanced NSCLC treated with Chemo-IO and IO monotherapy focusing on objective response rate (ORR: rate of partial response and complete response), progression-free survival (PFS), and overall survival (OS). We also assessed impact of antibiotic exposure in an independent cohort of 53 patients. Univariable and multivariable analyses were conducted along with a meta-analysis from similar studies. For the -60 d window, in the Chemo-IO group (N = 769), 183 (24%) patients received antibiotics. Antibiotic exposure was associated with worse ORR (27% vs 40%, p = 0.001), shorter PFS (3.9 months vs. 5.9 months, hazard ratio [HR] 1.35, 95%CI 1.1,1.6, p = 0.0012), as well as shorter OS (10 months vs. 15 months, HR 1.50, 95%CI 1.2,1.8, p = 0.00014). After adjusting for known prognostic factors in NSCLC, antibiotic exposure was independently associated with worse PFS (HR 1.39, 95%CI 1.35,1.7, p = 0.002) and OS (HR 1.61, 95%CI 1.28,2.03, p < 0.001). Similar results were obtained in the -60 + 42d window, and also in an independent cohort. In a meta-analysis of patients with NSCLC treated with Chemo-IO (N = 4) or IO monotherapy (N = 13 studies) antibiotic exposure before treatment was associated with worse OS among all patients (n = 11,351) (HR 1.93, 95% CI 1.52, 2.45) and Chemo-IO-treated patients (n = 1201) (HR 1.54, 95% CI 1.28, 1.84). Thus, antibiotics exposure prior to Chemo-IO is common and associated with worse outcomes, even after adjusting for other factors. These results highlight the need to implement antibiotic stewardship in routine oncology practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the demonstration of the deleterious impact of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The two currently largest meta-analyses corroborating the deleterious effects of antibiotics on the outcome of immunotherapy alone 3 or in combination with chemotherapy (chemo-immunotherapy) 4 involve >110,000 patients.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [4]
In the citing paper
“A meta-analysis of 105 studies and 46,000 cancer patients treated with ICIs convincingly showed that exposure to antibiotics was associated with shorter progression-free survival and overall survival in NSCLC patients.104”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [104]
In the citing paper
“the negative correlation between broad-spectrum antibiotic use and prognosis was, at least initially, independent of possible confounding factors including age, performance status and comorbidities 3,4 and was observed in patients receiving immunotherapy-based regimens but not in those receiving chemotherapy alone 91,92 .”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [4]
In the citing paper
“The two currently largest meta-analyses corroborating the deleterious effects of antibiotics on the outcome of immunotherapy alone 3 or in combination with chemotherapy (chemo-immunotherapy) 4 involve >110,000 patients.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [4]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825 · cited 1×
“Given increasing use of Chemo-IO as a mainstay fi rst-line therapy in patients with NSCLC, and recent approvals of Chemo-IO in the neoadjuvant setting 21 , there isa needto further understand the role of antibioticuse in clinical outcomes prior to the initiation of Chemo-IO.”
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · cited 1×
“The addition of chemotherapy to IO could already disrupt gut microbiota and potentially make the impact of antibiotic exposure less clinically signi fi cant 20 .”
Self-citationReck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670 · cited 1×
“Drugs that inhibit PD-1 or PD-L1 (PD-(L)1 blockade) alone (IO) or in combination with platinum-doublet chemotherapy (Chemo-IO) are now standard-of-care therapeutic regimens in patients with advanced non-small cell lung cancer (NSCLC) without a driver alteration 1 – 5 .”
Reproducible Summary Tables with the gtsummary Package
Sjoberg, D., Whiting, K., Curry, M., Lavery, J., & Larmarange, J. (2021) · The R Journal · doi:10.32614/rj-2021-053 · Cited by 1,290
Cited by
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 124
“This dysbiosis can be further compounded by iatrogenic insults such as antibiotics 16–19 , now validated as an independent negative prognostic factor across multiple oncology settings.”
Self-citationElkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 108
“Although broad-spectrum antibiotics have a detrimental effect on the microbiome and on overall survival of patients treated with ICIs 194 , selectively removing taxa that mediate an inappropriate immune environment in the microbiome could be achieved by selective antibiotics or decolonization…”
Self-citationTumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 63
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 41
Metadata
- Authors
- Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., Zitvogel, L., Rudin, C. M., Routy, B., Derosa, L., & Schoenfeld, A. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Inserm (FR)
- Corresponding author
- Elkrief, Arielle
- Schoenfeld, Adam J.
- ORCID
- Venue
- npj Precision Oncology
- Published
- 2024-07-16
- Volume
- 8
- Issue
- 1
- Pages
- 143-143
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC11252311
- OpenAlex
- W4400677411
- Cited by
- 68
- References
- 35
- Citations by year
- 2026: 36 · 2025: 30 · 2024: 2
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Damon Runyon Cancer Research Foundation (P30 CA008748, CI-98-18)
- Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
- Cancer Research Society
- Parker Institute for Cancer Immunotherapy
- Royal College of Physicians and Surgeons of Canada
- Agence Nationale de la Recherche (ANR-21-RHUS-0017)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- antibiotics, non-small cell lung cancer, immune checkpoint inhibitors, anti-PD-1 therapy, platinum-based chemotherapy, chemoimmunotherapy, objective response rate, progression-free survival, overall survival, prognostic factors, immune-related adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. https://app.cochat.ai/papers/10.1038/s41698-024-00630-w
- The paper
- Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., Zitvogel, L., Rudin, C. M., Routy, B., Derosa, L., & Schoenfeld, A. J. (2024). Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00630-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.